

1 **Title:** COVID-19 vaccination atlas: an integrative systems vaccinology approach

2 **Authors:** Wasim Aluísio Prates-Syed<sup>1,2,16</sup>, Dennyson Leandro Mathias da Fonseca<sup>3</sup>, Shahab  
3 Zaki Pour<sup>4</sup>, Lena F Schimke<sup>2</sup>, Aline Lira<sup>1,2,16</sup>, Nelson Cortes<sup>1,2,16</sup>, Jaqueline Dinis Queiroz  
4 Silva<sup>1,6,16</sup>, Evelyn Carvalho<sup>1,6,16</sup>, Igor Salerno Filgueiras<sup>2</sup>, Tania Geraldine Churascari  
5 Vences<sup>5</sup>, Lorena C. S. Chaves<sup>7</sup>, Gerhard Wunderlich<sup>5</sup>, Ricardo Durães-Carvalho<sup>4,8</sup>, Niels O.  
6 S. Câmara<sup>1</sup>, Haroldo Dutra Dias<sup>12</sup>, Hans D. Ochs<sup>11</sup>, José E. Krieger<sup>10</sup>, Helder I Nakaya<sup>6,13</sup>,  
7 Otávio Cabral-Marques<sup>1,3,6,15,16,+</sup>, Gustavo Cabral-Miranda<sup>1,2,6,16,+,\*</sup>.

8 **Emails:** [wasim.syed@usp.br](mailto:wasim.syed@usp.br), [dennyson@usp.br](mailto:dennyson@usp.br), [shahab.178@gmail.com](mailto:shahab.178@gmail.com),  
9 [igor.filgueiras@usp.br](mailto:igor.filgueiras@usp.br), [lenaschimke@hotmail.com](mailto:lenaschimke@hotmail.com), [cv.tania@usp.br](mailto:cv.tania@usp.br), [aline.lira@usp.br](mailto:aline.lira@usp.br),  
10 [nelson.cortes@usp.br](mailto:nelson.cortes@usp.br), [jaquelinedinis@gmail.com](mailto:jaquelinedinis@gmail.com), [evelyn.carvalho@unesp.br](mailto:evelyn.carvalho@unesp.br),  
11 [lorenacschaves@gmail.com](mailto:lorenacschaves@gmail.com), [gwunder@usp.br](mailto:gwunder@usp.br), [rscarval@gmail.com](mailto:rscarval@gmail.com), [niels@icb.usp.br](mailto:niels@icb.usp.br),  
12 [harolddodd@gmail.com](mailto:harolddodd@gmail.com), [hans.ochs@seattlechildrens.org](mailto:hans.ochs@seattlechildrens.org), [sabinoec@usp.br](mailto:sabinoec@usp.br),  
13 [j.krieger@hc.fm.usp.br](mailto:j.krieger@hc.fm.usp.br), [hnakaya@usp.br](mailto:hnakaya@usp.br), [otavio.cmarques@usp.br](mailto:otavio.cmarques@usp.br), [gcabral.miranda@usp.br](mailto:gcabral.miranda@usp.br)

14 **Affiliations:**

- 15 1. Department of Immunology, Institute of Biomedical Sciences (ICB), University of  
16 São Paulo (USP), São Paulo, Brazil.
- 17 2. The Interunits Graduate Program in Biotechnology of the University of São Paulo, the  
18 Butantan Institute, and the Technological Research Institute of the State of São Paulo,  
19 Brazil.
- 20 3. Interunit Postgraduate Program on Bioinformatics, Institute of Mathematics and  
21 Statistics (IME), University of Sao Paulo (USP), Sao Paulo, Brazil.
- 22 4. Laboratory of Molecular Evolution and Bioinformatics, Department of Microbiology,  
23 Biomedical Sciences Institute, University of São Paulo, São Paulo, Brazil;
- 24 5. Department of Parasitology, Institute of Biomedical Sciences (ICB), University of São  
25 Paulo (USP), São Paulo, Brazil.
- 26 6. Department of Clinical and Toxicological Analyses, School of Pharmaceutical  
27 Sciences, University of São Paulo, São Paulo, Brazil.
- 28 7. Department of Microbiology and Immunology, School of Medicine, Emory  
29 University, Atlanta, Georgia, United States.
- 30 8. São Paulo School of Medicine, Department of Microbiology, Immunology and  
31 Parasitology, and Department of Morphology and Genetics, Federal University of São  
32 Paulo (UNIFESP), São Paulo, SP, Brazil.
- 33 9. Department of Infectious and Parasitic Diseases, Faculty of Medicine, University of  
34 São Paulo, São Paulo, Brazil
- 35 10. Heart Institute, Clinical Hospital, Faculty of Medicine, University of São Paulo,  
36 Brazil; Laboratory of Genetics and Molecular Cardiology, Clinical Hospital, Faculty  
37 of Medicine, University of São Paulo, Brazil.
- 38 11. Department of Pediatrics, University of Washington School of Medicine, and Seattle  
39 Children's Research Institute, Seattle, WA, USA.
- 40 12. Department of Neuroscience, Institute of Biomedical Sciences, Federal University of  
41 Minas Gerais (UFMG), Belo Horizonte, Brazil
- 42 13. Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
- 43 14. DO'R Institute for research, São Paulo, Brazil
- 44 15. Department of Medicine, Division of Molecular Medicine, University of São Paulo  
45 School of Medicine, São Paulo, Brazil.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

46 16. Institute of Tropical Medicine, Faculty of Medicine of the University of São Paulo,  
47 Brazil

48 \*Correspondence to: [gcabral.miranda@usp.br](mailto:gcabral.miranda@usp.br) or [gcabral.miranda@gmail.com](mailto:gcabral.miranda@gmail.com), Gustavo  
49 Cabral-Miranda, Institute of Tropical Medicine, Faculty of Medicine of the University of São  
50 Paulo, Brazil

51 + Equal contribution as supervisor and senior author.

52 **Abstract:**

53 The COVID-19 vaccinations have played a significant role in controlling the pandemic. To  
54 elucidate their impact on the immune system, a COVID-19 vaccination atlas was developed  
55 through an integrative systems vaccinology approach. The atlas includes both healthy  
56 individuals and those infected with or without prior vaccination, and covers the administration  
57 of five vaccines in different regimens: Covilo®, Zifivax®, Vaxzebria® or Covishield®,  
58 Spikevax®, and Comirnaty®. Critical markers were identified to discriminate the different  
59 types of vaccines and infection, in which infection was associated with GATA3, ZNF3,  
60 KMT2A, ASXL1, SP100, and GZMM, and vaccine types were marked by ITGAM, ACTG1,  
61 LGALS3, and STAT5B. Additionally, the immunological signatures of heterologous  
62 vaccination and infection were described, and it was also shown how a full vaccination  
63 regimen markedly limited the shift of immune responses during natural infection, thereby  
64 constraining disease progression. Finally, the common transcripts shared across COVID-19  
65 vaccines and vaccines against other pathogens were described.

## 66 Main text

### 67 1. Introduction

68 Coronavirus Disease 2019 (COVID-19) is a respiratory disease caused by Severe  
69 Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), with its first documented  
70 outbreak in Wuhan, China, in 2019<sup>1</sup>. The emergence of variants of concern (VOCs) urged  
71 adjustments in strategies to effectively control their spread due to the heterogeneity of  
72 symptoms, severity, transmission, and decreased efficacy of vaccines against new VOCs,  
73 especially the Omicron variant (Chung et al., 2021; Xia et al., 2022).

74 Remarkably, it is estimated that COVID-19 vaccinations prevented more than 14  
75 million deaths in only one year after global vaccination enrollment<sup>4</sup>. This was accomplished  
76 by breakthrough innovations in vaccinology, in addition to global efforts to fund worldwide  
77 clinical trials, including classical and new-generation vaccines<sup>5</sup>. The mRNA vaccines (RNA)  
78 Comirnaty® (BNT162b2, BNT) and Spikevax® (mRNA-1273, MO), the viral vectored (VV)  
79 vaccines Covishield®/Vaxzevria® (AZD1222, ChAdOx-1, ChAd) and Jcovden® (Janssen),  
80 and inactivated vaccines (IN) such as Coronavac® and Covilo® (BBIBP-CORV, BBIBP)  
81 were among the first and most used vaccines worldwide until 2023<sup>6</sup>. Particularly, ChAd and  
82 BNT were the most used vaccines during the first years of vaccination and 2 and 3-dose  
83 heterologous regimens were widely used and assessed<sup>7,8</sup>. The combination of different  
84 vaccines and platforms shows how classical and new-generation vaccines can help control  
85 epidemics and potentially trigger complementary systemic immune responses that individual  
86 vaccine technologies are intrinsically incapable of<sup>8-11</sup>. The complete homologous vaccination  
87 regimen showed high efficacy in clinical trials against COVID-19, as high as 95.0%, 94.1%,  
88 and 90% for new-generation vaccines, such as BNT, MO, and ChAd, respectively<sup>11-13</sup>.  
89 Classical technologies, such as inactivated virus (IN), and protein subunit (SU) vaccines, have  
90 also shown high efficacy and effectiveness. BBIBP and Zifivax® (ZF2001) had 78.1% and  
91 75.7% efficacy against symptomatic infections, respectively<sup>14,15</sup>. Although these vaccines  
92 were initially tested and approved in homologous regimens, heterologous vaccination has  
93 been tested in clinical trials and real-world scenarios to address ongoing waves of infection  
94 and new VOCs<sup>8,16</sup>.

95 To understand how different vaccination regimens and vaccine technologies affect the  
96 immune system in healthy individuals and infected patients during, and after infection by  
97 SARS-CoV-2, it was integrated RNAseq data from five distinct studies that include  
98 vaccinations with Covilo®, Vaxzevria® or Covishield®, Spikevax®, Comirnaty®, and  
99 Zifivax®. These studies, however, present data from different time points, populations and  
100 regimens, and there is a need to obtain a unified perspective of their immunological signatures.  
101 This study introduces a systems vaccinology atlas that delineates shared and individual  
102 profiles across conditions in both healthy and infected individuals. The findings indicate that  
103 completing a vaccination regimen can effectively limit disease progression. Additionally, it  
104 demonstrates that heterologous vaccination strategies can diversify immunological signatures,  
105 potentially enhancing protection against the disease. Furthermore, the study explores immune  
106 responses induced by vaccines targeting other pathogens and reveals a substantial overlap in  
107 genes related to the innate immune system with COVID-19 vaccines.

108



## 109 2. Results

### 110 Immune-related gene expression varies by vaccine type, regimen, and infection status.

111 A total of 562 samples were analyzed, sourced from peripheral blood mononuclear  
112 cells (PBMCs) of 245 participants involved in five distinct studies (**Table 1, Fig. 1A**). These  
113 participants were either vaccinated (V) with one or more of the four different types of vaccines  
114 (IN, SU, RNA, and VV), which comprised both homologous (HO) and heterologous (HE)  
115 vaccination regimens and were administered in one (V1), two (V2), or three doses (V3), or  
116 were infected patients (I) with or without prior vaccination (**Fig. 1B-C, Fig. S1-2**). Many  
117 issues were identified with the GSE206023 count matrix, in which most of the genes were  
118 annotated in GenBank IDs with multiple identifier versions for the same genes. Moreover,  
119 only 10% of these identifiers could be annotated, comprising less than 2% of the immune  
120 genes, in contrast to more than 90% present in the other datasets. Given the importance of this  
121 dataset regarding the diversity of vaccine technologies, a decision was made to reprocess the  
122 read files in FASTQ and align it with the reference transcriptome using pseudoalignment in  
123 the Kallisto package<sup>17</sup>. While other datasets employed HISAT2, pseudoalignment was chosen  
124 due to its superior speed, robustness, and lower computational resource requirements  
125 compared to HISAT2.<sup>18</sup>

126 The temporal dynamics of differentially expressed genes (DEGs) was influenced by  
127 vaccine type, number of doses, and administration regimen. This happened across  
128 convalescent and non-convalescent individuals, as well as infected patients with previous  
129 vaccination (**Fig. 2A, Fig. S3**). Notably, the BNT vaccine exhibited a significant increase in  
130 total DEGs across the three doses, with three DEGs six days after the first dose (BNT V1),  
131 followed by 613 and 96 DEGs 1 day after the second (BNT V2) and third doses (BNT V3),  
132 respectively, with a more substantial increase with two doses of BNT followed by a single  
133 dose of MO (BNT-MO V3) (**Fig. 2A**). In contrast, it was observed that the ChAd vaccine  
134 exhibited a divergent pattern compared to BNT in non-convalescent individuals, with  
135 decreased up- and downregulated DEGs over the first week after two homologous doses  
136 (ChAd V2), and a higher number of DEGs in the heterologous vaccinations (ChAd-BNT V2  
137 and ChAd-BNT V3) (**Fig. 2A, Fig. S3**). A similar trend was observed in homologous and  
138 heterologous vaccinations with the BBIBP vaccine after a third dose (**Fig. 2A, Fig. S3**). It was  
139 evident that homologous vaccination with an inactivated virus vaccine does not generate  
140 significant DEGs in a third dose (BBIBP V3) and thus requires heterologous vaccination with  
141 a different technology, such as a SU vaccine (ZF2001 V3) (**Fig. 2A, Fig. S3**).

142 Furthermore, infections in vaccinated and unvaccinated patients notably affected the  
143 number of downregulated DEGs (**Fig. 2A, Fig. S3**). Among unvaccinated infected  
144 individuals, DEGs were higher in severe disease cases than in moderate cases over 51 days.  
145 Conversely, in infected patients with prior complete vaccination, primarily mild and moderate  
146 disease, this number was at least 10 times lower. However, infected hospitalized patients with  
147 moderate and severe disease who were vaccinated with a single dose of BNT 10-11 days  
148 before hospitalization, the number of DEGs was similar to that of infected patients on days 10  
149 and 26. This pattern could also be influenced by the age range (71-90 years) of these patients,  
150 which is a major risk factor for COVID-19<sup>19</sup>. Of the four infected patients, three recovered,  
151 and one died (**Fig. S3**). The surviving patients continued dexamethasone treatment and  
152 received a second dose of the vaccine 40 days post-infection<sup>20</sup>. Samples were collected 15-20  
153 days post-vaccination, exhibiting more DEGs than at a later time post-vaccination in non-  
154 convalescent individuals with BNT or ChAd (**Fig. 2A**). The gene expression patterns in  
155 unvaccinated and single-dose vaccinated patients during the second infection were similar,

156 but vaccinated individuals exhibited a notable, threefold reduction in DEGs compared to with  
157 unvaccinated counterparts. Only in the total DEGs analysis, without discriminating by  
158 ontology (immune and non-immune), was an apparent relationship between vaccine type,  
159 disease severity, and time.

160 Upon filtering immune-related DEGs, it became clear that the fraction of immune-  
161 related genes decreased over time in vaccinees and infected patients (**Fig. 2A, Fig. S3**).  
162 Specifically, this investigation focused solely the immune-related genes excluding genes from  
163 the BCR and TCR repertoire [immunoglobulin chains (IG@) and T-cell receptors (TR@)].  
164 Particularly in infected patients, the first days showed a greater fraction of immune genes,  
165 which decreased over time, whereas the number of other non-immune-related genes increased  
166 (**Fig. 2A, Fig. S3A**). In addition, infected patients with prior complete immunization showed  
167 fewer DEGs and a smaller fraction of immune genes. Nevertheless, vaccination results in the  
168 activation substantially more immune genes, which follow proportionally to other genes,  
169 either increasing or decreasing, depending on the vaccine type. This contrast indicates that the  
170 immune response induced by vaccines is quantitatively more balanced in terms of the  
171 expression of immune genes than infection. To identify patterns among these conditions,  
172 immune-related and non-immune DEGs were compared distinctively (q-value < 0.10) (**Fig.**  
173 **2B, Fig. S4A**). It was observed that the majority of shared genes among the different vaccine  
174 types were non-immune genes, such as ANKRD22, GBP1P1, GPRB4, and HES4 (**Fig. S4A-**  
175 **B**). Moreover, the most shared genes, such as LRRN3, ADAMTS2, and FAM209B, were  
176 more present among infected patients (**Fig. 5B**). This shows the role of other processes in  
177 vaccination and, to a greater extent, infection.

178 To understand these non-immune processes during vaccination, the analysis focused  
179 on the non-immune genes. It was found that a majority of these genes were related to  
180 ubiquitous cellular and metabolic processes, and the regulation of biological processes (**Fig.**  
181 **2A-B, Fig. S4**). However, the subsequent analysis specifically targeted immune genes. The  
182 shared immune DEGs exhibited one central cluster associated with the groups infected for the  
183 first time (vaccinated and unvaccinated) and another cluster comprising the first day of  
184 vaccination with homologous or heterologous second and third doses of ChAd, BNT, and MO  
185 (**Fig. 2B**). Notably, the number of shared genes among infected groups was 2- to 10-fold  
186 higher than non-convalescent-vaccinated groups. In addition, it was observed a decrease in  
187 shared DEGs between infected patients with prior vaccination (BNT-I) and infected patients  
188 with prior infection and prior vaccination (I-BNT-I), in a similar proportion to non-  
189 convalescent vaccinated groups, which was not evident in the non-immune DEGs context  
190 (**Fig. 3B, Fig. S4A**). This finding was also associated with vaccine type, viral vector vaccines  
191 (ChAd and ChAd-BNT), and subunit vaccines (ZF2001), which were more evident with non-  
192 immune DEGs (**Fig. S4A**).

193 In contrast, there was a noticeable decrease in the number of genes on subsequent days,  
194 particularly on day 7, suggesting the initiation of homeostatic processes over time. This  
195 reduction in DEGs becomes more pronounced on subsequent days. However, this decrease  
196 contrasts with the trend observed with increasing doses, particularly notable in homologous  
197 RNA vaccines and heterologous ChAd with subsequent vaccination with BNT. This indicates  
198 a broader activation of diverse genes with a higher number of doses. Particularly, vaccination  
199 with BNT following one or two doses of ChAd led to a significantly greater number of total  
200 DEGs compared to the two-dose homologous regimen of either vaccine (**Fig. 2A-B, Fig. S4**).  
201 Comparing to the two doses of ChAd on day 3, there was a three-fold increase in upregulated  
202 DEGs, which reduced by half on day 7. Conversely, downregulated DEGs were 13-fold higher

203 in the ChAd-BNT regimen but increased two-fold on day 7. Remarkably, even though the  
204 assessment was conducted only one day post-vaccination, upregulated DEGs exhibited in the  
205 ChAd-ChAd-BNT regimen were approximately two-fold higher than those with two doses of  
206 ChAd and 1.2-fold higher than those with BNT-MO.

207 In contrast, the number of up- and downregulated genes was nearly equivalent in  
208 infected individuals, regardless of prior vaccination status (**Fig. 2A, Fig. S4A**). Additionally,  
209 genes from unvaccinated infected individuals were largely constrained within their group and  
210 had a limited overlap with vaccinated individuals.

211 To describe the immune transcriptome of individual vaccination regimens, we  
212 compared all the genes present in the datasets with the immune system related genes (**Fig.**  
213 **4D**). Following this comparison, the enrichment of gene sets associated with immune  
214 responses was analyzed. (**Fig. 4C**).

### 215 **Limited Immunological Profile Observed with Three Homologous doses of BBIBP**

216 The BBIBP exhibited enrichment of processes associated with the innate immune system,  
217 including the antiviral response mediated by interferons, neutrophils, eosinophils, and  
218 monocytes, which were consistently found to be negatively regulated (**Fig. 4C**). Further  
219 analysis of gene expression within these processes and cells revealed specific genes of interest  
220 (**Fig. S4-7**). On day 14, we identified genes associated with inflammation (NLRP9,  
221 upregulated), immune regulation (IDO2), macrophage-mediated antiviral response (CCL3,  
222 downregulated), neutrophil activation (CXCL8), and lymphocyte-macrophage signaling  
223 (WNT4, upregulated)<sup>21</sup>. On day 28, a transcription factor (NFKBIA, downregulated) present  
224 in ARPP and B cells, which regulate immune system processes, and CCL2 (downregulated),  
225 a monocyte chemokine, were observed.

### 226 **ZF2001 as Heterologous Booster Elicits Distinct Immune Response Profile**

227 A heterologous regimen with the ZF2001 vaccine in individuals who had previously received  
228 two doses of the BBIBP vaccine resulted in a distinct gene expression profile compared to the  
229 homologous vaccine. Although most DEGs were upregulated, a small fraction of genes related  
230 to the immune system were downregulated (**Fig. 2A**). On the seventh day post-vaccination,  
231 there was a suppression of genes associated with inflammatory processes (IL1RN, FOSL2,  
232 and CD58), antiviral response and interferons (CXCL2, CXCL3, CCL3, CCL4, CCL20,  
233 BCL3, ADM, LGALS3, FAU), as well as genes related to antigen recognition and  
234 presentation (TNFAIP3, FOSL1, RAB3B, and ICAM). This suppression also extended to  
235 genes expressed in eosinophils (VAMP2), NK cells (RNF19B), dendritic cells (NFKBIA,  
236 FOSL1), T cells (IL2), B cells, and immunoglobulin-mediated responses (BCL3, BCL6) (**Fig.**  
237 **2C, Fig. S6-9**).

238 On the other hand, a predominance of upregulated genes was observed on the seventh day,  
239 particularly associated with other chemokines (CX3CL1, CXCL8, CXCL14, CCL8,  
240 CX3CL1), mast cells (CPLX2, CLNK, LGALS3), ARPP (ITGB8, TRIL), APCs (ADGRF5,  
241 FLT1, IL33, WNT4), adaptive response processes and cells (CACNB4, EOMES, SPNS2,  
242 BCAR1), as well as the complement system (**Fig. S6-9**). Specifically, within the complement  
243 system, genes from the classical pathway (C4B and C4BPB) and lectins (MASP1 and  
244 MASP2) were overexpressed (**Fig. S6-9**). In the adaptive immune system, there were genes  
245 related to T cell activation (IL13, EPHB1, TNFAIP8L2, TARM1), specifically Th2 response

246 (IL33), Th17 (CCR2), TCD8 (EMP2), B cell and Ig-mediated response (WNT3A) (**Fig. S6-**  
247 **9**).

## 248 **Viral Vected Vaccine ChAd Induces Early Gene Expression of Complement and** 249 **Adaptive Immune Systems**

250 Genes related to T cells and the cellular response to the viral vector were expressed as early  
251 as the third-day post-vaccination with the first dose. Notably, genes such as CCNB2 and  
252 CAV1, which play roles in the cell cycle and T cell activation, respectively, exhibited  
253 sustained expression levels up to the seventh day. Additionally, the innate immune system  
254 processes are enriched, including interferon-mediated antiviral responses, acute phase  
255 response proteins (ARPP), and NK cell, related proteins along with upregulated genes from  
256 the complement system associated with the alternative pathway (CFB and CFD) (**Fig. S7-9**).

257 It is also essential to highlight the distinct expression of genes related to humoral responses  
258 on the third and seventh days (**Fig. S8**). These expression patterns were also observed in B-  
259 cell genes, with overexpression between days 3, 6, and 7, returning to the initial profile by the  
260 sixth day. Conversely, except for genes associated to cellular response, B cells processes, and  
261 the humoral immune response were enriched on the first day after the second dose. However,  
262 gene-level analysis still revealed diverse and high gene expression at this stage, especially for  
263 the cytokine CCL2 and immunoregulatory enzyme IDO1. When comparing genes related to  
264 the humoral response between doses, it was noted that these genes were less expressed and  
265 less diverse at the second dose. On the third day, only two DEGs associated with the humoral  
266 response were identified (SYK and KIT). Particularly, on day 7, CD27, a gene involved in  
267 immunoglobulin synthesis,<sup>22</sup> was increased after the first dose and suppressed after the second  
268 dose.

## 269 **Distinct Gene Expression Patterns Elicited by mRNA Vaccines BNT and MO**

270 The mRNA vaccines BNT and MO demonstrate distinct gene expression patterns. Six days  
271 after the first dose of BNT, only 3 DEGs were identified, with IFI27 being the only immune-  
272 related gene (**Fig. 2A, Fig. S4-7**). Subsequent second and third BNT doses revealed elevated  
273 activation of antiviral and interferon responses, ARPP, and the function of neutrophils,  
274 eosinophils, monocytes and dendritic cells (**Fig. 4C**). These sets were similarly enriched  
275 following the third homologous vaccination, except for dendritic cells. A third heterologous  
276 vaccination with MO induced dendritic cell function, inflammation, and the activation of the  
277 cellular adaptive immune system. Notably, IFI27 expression was exclusive to all BNT doses  
278 except for the third dose of MO (**Fig. S4-7**). Neutrophils shared genes in various vaccination  
279 regimens, including CCL8, CXCL9, and CCL2 (**Fig. S4-7**)<sup>23</sup>. In addition, eosinophils  
280 exhibited pronounced CCL3L1 expression following MO vaccination, which plays a pivotal  
281 role in virus clearance from the lungs<sup>24</sup>.

## 282 **Immune Signatures in Infected and Convalescent Patients Before and After Vaccination** 283 **with BNT**

284 To understand the impact of vaccination before and after infection, we analyzed infected and  
285 convalescent patients. We found that innate immune cells and processes were highly activated  
286 and persisted for several days, especially interferons 1 and 2, neutrophils, APCs, and  
287 bacterium-directed PRRs (TLR4 and NOD) (**Fig. 4C, Fig. S4-7**). Additionally, B-cell  
288 processes, including chemotaxis and homeostasis, are activated (**Fig. 4C, Fig. S4-7**). There  
289 was also a Th2 response in BNT-I (D26, mild), although T cell processes were predominantly



290 downregulated under other infection conditions. In a gene-level analysis, many genes related  
291 to the adaptive immune system were upregulated and downregulated. Likewise, it was evident  
292 that infection induced different subsets of genes compared to vaccination in every immune  
293 process and cell type (**Fig. S4-7**). Considering the innate immune system and classical  
294 pathway complement system genes (such as CR1 and C1R), high and persistent gene  
295 expression, especially those associated with inflammation (e.g., IL10, HMGB2, ELANE, and  
296 NLRP6), activation of neutrophils (e.g., CD177, ANXA3, and IL18RAP) and mast cells (e.g.,  
297 S100A12 and SLC15A4), may be associated with the initiation of cytokine storms, allergic  
298 reactions, and thrombosis<sup>25,26</sup>. Although most genes participating in adaptive immune system  
299 processes were highly downregulated, there were also many highly expressed genes in the  
300 humoral response, including genes related to Ig-mediated responses, ARPP, and other B-cell  
301 processes, as well as in cellular response and T- cell processes. This pattern varied among  
302 convalescent and infected patients who had received prior vaccination, regardless of whether  
303 they had a completed or incomplete vaccine regimen (**Fig. S4**).

### 304 **Stratification of COVID-19 vaccination and infection using multivariate analyses**

305 To describe the similarities and differences among all conditions, it was conducted a  
306 Principal components analysis (PCA) with all immune DEGs (**Fig. 3A-D**). Principal  
307 component 1 (PC1) accounted for 66.8% of the variance, whereas PC2 accounted for 15.7%,  
308 totaling 81.9%. PC1 was predominantly defined by genes associated with interleukin (IL)  
309 signaling pathways (IL18RAP, SOS2, MAP2K6), apoptosis (HMGB2), inflammation-related  
310 processes (RC3H1, ALOX5, PPARG, and FCER1A), as well as processes linked to  
311 lymphocytes (ETS1), particularly to T cells (VNN1, CD6, TESPA1, RPL22, PCLG1, TCF7,  
312 TRAT1, and CD3G) (**Fig. 3C**). On the other hand, PC2 was defined by genes related to  
313 antiviral and interferon responses (IFI35, IFITM3, STAT1-2, IDO1, ADAR, BST2, GBP1,  
314 and PML), as well as APCs (BATF2, LILRB1) and antigen receptors, processing and  
315 presentation (ARPP) (TAP2, PDIA3, TRIM26, and CTSS) (**Fig. 3D**).

316 The results revealed the presence of three primary clusters (**Fig. 3A**). The first  
317 significant cluster indicated patients with ongoing infection, characterized by genes associated  
318 with IL-signaling pathways, apoptosis, and inflammation-related processes in cluster 1 (**C1**;  
319 **Fig. 3A,C**). While this cluster included specific individuals with previous vaccination, we did  
320 not anticipate a substantial influence of vaccination, particularly considering that it was  
321 administered 10 days before the onset of COVID-19 symptoms. Nevertheless, it is evident  
322 that patients who received a complete vaccination regimen and were subsequently infected  
323 (BNT-I), as well as a patient who received a second dose of BNT 10 days after recovery  
324 (BNT-I-BNT, D51), showed overlap with Cluster 2 (C2). The C2 cluster comprises  
325 homologous vaccinations for both convalescent patients and non-convalescent individuals.  
326 Additionally, healthy-vaccinated individuals were part of this cluster, but it also included  
327 patients with two infections (without severe outcomes) and one patient initially experiencing  
328 severe disease 51 days after the onset of symptoms, who were hospitalized and treated with  
329 steroids. Given that this cluster occupies the central position in the plot and represents  
330 comparatively healthy conditions, the proximity of eigenvalues from the first cluster to the  
331 second cluster suggests an ongoing, time-dependent homeostatic process. In contrast, the third  
332 cluster (C3) consisted of homologous and heterologous vaccinations involving genetic-based  
333 vaccines such as BNT, ChAd, and MO, specifically within the initial three days post-  
334 vaccination. This cluster is characterized by genes in PC2 and shares a minimum number of  
335 certain genes with infected patients in C1. Nevertheless, the expression of the top 20  
336 contributing genes in PC2 was significantly higher in C3 than in C1 conditions (**Fig. 3B,D**).

337 These differences were marked by genes such as IDO1, IL31RA, and LILRB1, which were  
338 not expressed during infection and are associated with antimicrobial response, chemotaxis,  
339 and MHC1 presentation, respectively.

## 340 **Machine learning classification of COVID-19 vaccine types and infection based on** 341 **immune genes**

342 Using the PCA results, genes in PC1 and PC2 ( $\cos^2 > 0.5$ ) were filtered and a random  
343 forest model was trained for classification based on the variable “type”, including infection  
344 and the different vaccine types (**Fig. 4A**). This model demonstrated remarkable performance,  
345 with an accuracy of 91.2%, an area under the receiver-operator curve (ROC) of 0.990, and an  
346 out-of-bag (OOB) error of 0.086. The main gene predictors were associated with  
347 transcriptional regulation (GATA3, ZNF3, KMT2A, and ASXL1), antiviral response  
348 (SP100), granzyme (GZMM), ARPP (ITGAM, ACTG1, LGALS3), and T cell response  
349 (STAT5B) (**Fig. 4B**). The high expression of the transcriptional regulation associated genes  
350 GATA3, ZNF3, KMT2A, and ASXL1, an antiviral response gene (SP100), and the granzyme  
351 GZMM, were key markers for infection, along with the suppression of genes that play roles  
352 in ARPP (ITGAM, ACTG1, LGALS3), and T-cell response (STAT5B) SP100 was also  
353 notably expressed in vaccination, in the first 3 days after the second and third doses of both  
354 homologous and heterologous regimens. LGALS3 was also markedly expressed in the first 3  
355 days of vaccination with ChAd. This observation aligns with the fact that viral vectored  
356 vaccines, like ChAd, act through certain infection associated mechanisms to deliver genetic  
357 material into the nucleus<sup>27</sup>.

## 358 **Comparative Analysis of Vaccines Against Other Pathogens**

359 Understanding how COVID-19 vaccines relate to classical and consolidated vaccines  
360 used in routine immunization is essential. Therefore, all immune-related DEGs associated  
361 with various vaccines, including COVID-19, were compared using MSigDB Vax collection  
362 <sup>28</sup>. The dataset was manually annotated and selected all up- and downregulated genes from  
363 vaccination-only sets (**see Methods, Fig. 1A**). This approach originated from several gene  
364 sets, including those correlated with antibody titers, T-cell responses, and training sets. To  
365 understand the extent of gene overlap, was performed a gene-level analysis of these shared  
366 genes from PBMC-derived samples, to match the COVID-19 conditions, while filtering DEGs  
367 with  $-1 < L2FC > 1$  (**Fig. 5A-C, Fig. S8 and 9**).

368 The analysis uncovered a notable overlap of genes, both up- and downregulated,  
369 between vaccines targeting viruses and bacteria based on inactivated (IN) and live-attenuated  
370 (LA) pathogens and COVID-19 vaccines (**Fig. 5A-C**). This overlap was most prominent in  
371 the initial two weeks and following the second and third doses. Specifically, downregulated  
372 DEGs were predominantly associated with infection, particularly with LA vaccines (**Fig. 5A**).  
373 Conversely, upregulated DEGs were common among vaccinated individuals, comprising both  
374 non-convalescent and convalescent individuals. This overlap extended to include infected  
375 patients who had undergone prior one-dose vaccination.

376 The observations revealed two main clusters of genes, predominantly representing the  
377 innate and adaptive immune systems (**Fig. S6**). While the second cluster encompasses genes  
378 present in the adaptive immune system, these genes also exhibit a lower degree of overlap  
379 with the innate immune system. Notably, the second cluster appeared more heterogeneous and  
380 demonstrated significantly fewer shared genes across vaccines than the first cluster. In this

381 first cluster, we observed that COVID-19 vaccines and others shared most innate genes that  
382 also play a role in the adaptive immune system (**Fig. 5D**). Some of the most common genes  
383 between vaccines included chemokines and receptors (CCL2, CCL3, CCL8, CCL20, CCR1,  
384 and CXCL8), interferons and antiviral responses (IRF1, IFIT1, STAT1, and STAT2), ARPP  
385 (TAP1, TAP2, HLA-DMB, and HLA-DMA), and some adaptive immune system genes  
386 (RIGI, FAS, CD83, BCL6, and FCER1G) (**Fig. 5B**). On the other hand, some of the genes  
387 present mainly in COVID-19 vaccine conditions are chemokines, such as CCL2, which play  
388 a diverse role in the innate, adaptive, and complement systems (**Fig. 5C**). CCL2 is also shared  
389 with the monovalent influenza vaccine adjuvanted with AS03 and the LA vaccine Fluzone®  
390 <sup>29</sup>. Although most non-COVID-19 vaccines sharing genes with COVID-19 vaccines are  
391 targeted against the influenza virus, Stamaril®, a yellow fever LA vaccine, shares many innate  
392 immune system genes with COVID-19 vaccines <sup>30</sup>. Indeed, an overrepresentation analysis  
393 (ORA, FDR < 0.25) of immune genes showed that general leukocyte processes and antiviral  
394 and interferon processes were enriched in most vaccines and vaccine types (**Fig. 5E**). VV  
395 vaccines against COVID-19 and tuberculosis (MVA85A) were significantly (qvalue < 0.10)  
396 enriched with genes related to eosinophils, monocytes, and neutrophils (**Fig. 5E**).

## 397 **Discussion**

398 This COVID-19 vaccination atlas comprehensively analyzes the dynamic and diverse  
399 immune responses generated by different vaccination strategies against COVID-19. These  
400 strategies include homologous and heterologous vaccination regimens, diverse vaccine types,  
401 and consideration of prior vaccination status at the time of infection, alongside the time  
402 elapsed since infection (**Fig. 1A**).

403 The analysis reveals that immune-related genes constitute a smaller proportion of the  
404 total DEGs than other biological processes, including cellular, metabolic, and regulation of  
405 biological processes (**Fig. 2A, Fig. S4**). A limitation of this analysis by gene ontology of  
406 biological process is that some genes that are not annotated as immune play ubiquitous roles  
407 in cellular and metabolic processes present in immune cells. This can also be attributed to the  
408 inoculation of immunogens through syringe injection, which leads to local and limited tissue  
409 damage at the injection site. Indeed, intramuscular injections are prone to human errors, and  
410 questions remain regarding which injection site and procedure are optimal and safest <sup>31</sup>. This  
411 vaccine administration issue and the molecular characteristics of different vaccine platforms  
412 might explain reactogenic behavior in some individuals. In the context of infection, this  
413 pattern illustrates the regulation of numerous genes influenced by viral infection cycle  
414 processes and the host response <sup>32,33</sup>. This variability is primarily attributed to diverse response  
415 mechanisms among individuals, impacting disease progression or immunity<sup>34</sup>. However, this  
416 aspect will not be discussed in more details since it diverges from the primary objective of our  
417 study, which focuses on describing the transcriptome of the immune system. Nonetheless, it  
418 is noteworthy as it raises questions regarding non-immunological factors and their role in  
419 vaccination and disease development.

420 Moreover, it was found that these DEGs are highly shared between the studied  
421 conditions, encompassing both infection and vaccination conditions. In addition, a higher  
422 representation of immune-related genes was observed in the vaccination group compared to  
423 infection (**Fig. 2A**). Specifically, genes associated with inflammation, the complement  
424 system, neutrophil function, antiviral responses, and interferon pathways exhibit prolonged  
425 activation during infection, while adaptive immune-related genes are significantly  
426 downregulated (**Fig. S4-7**). In contrast, vaccination triggers the activation of chemokines and  
427 adaptive immune-related genes.



428 The surge in up- and downregulated DEGs in the early days after the second and third  
429 doses of BNT or MO indicates the ability to activate the innate immune response. Considering  
430 the rapid mRNA expression, post-inoculation might also trigger antigen-presenting cells to  
431 initiate an adaptive immune response<sup>35</sup>. Notably, despite having the same mRNA platform as  
432 BNT and encoding the same spike amino acid sequence, the MO vaccine differs in nucleotide  
433 sequence due to codon optimization and the absence of pseudouridine modification<sup>36,37</sup>.  
434 However, whether this substantial increase is attributable to an immune response to the third  
435 dose, the technology, or other factors, such as LNP composition, remains unclear.

436 The heterologous vaccination regimen was also explored with different types of  
437 vaccines, namely ChAd and BNT, and BBIBP and ZF2001. It was found that it can contribute  
438 to the diversification of immune responses, address some of the technological limitations of  
439 the vaccine platforms, and consequently enhance protection against COVID-19.

440 The ChAd vaccine contains a chimpanzee adenovirus viral vector that shares epitopes  
441 with prevalent human adenoviruses, which can trigger an adaptive immune response against  
442 the vector<sup>38</sup>. It is therefore possible that the administration of multiple doses of the vaccine  
443 may generate antibodies targeting the vector, potentially limiting the delivery of genetic  
444 material, unlike mRNA vaccines<sup>39</sup>. Hence, heterologous vaccination is a clinical and  
445 immunologically important option, allowing individuals who receive the complete  
446 homologous ChAd regimen to obtain better protection through vaccination with vaccines that  
447 use different technologies, particularly those based on mRNA<sup>16,40</sup>. Nevertheless, the  
448 discussion regarding the continued efficacy of the ChAd viral vector in these individuals  
449 compared to other antigen vaccine formulations is crucial.

450 Heterologous mRNA vaccination regimens, especially those following the ChAd  
451 vaccine, demonstrate similarity to the second and third mRNA homologous and heterologous  
452 vaccinations. This can be advantageous for a vaccination regimen that is initiated by a VV  
453 vaccine and boosted by mRNA vaccines, potentially mitigating the impact of antibodies  
454 directed against the viral vector. However, the use of BNT as a third dose after two ChAd  
455 doses is mainly associated with antiviral and interferon responses as well as neutrophils.  
456 Additionally, as the samples were limited to the first day after vaccination in this condition,  
457 we could not assess the impact of these responses on the adaptive immune system.

458 The Covilo®/BBIBP vaccine is an inactivated virus vaccine formulated with alum  
459 adjuvant and evaluated in clinical trials with a homologous two-dose regimen (Wang et al.,  
460 2020; Al Kaabi et al., 2021; Zhang et al., 2022). The regimen of three homologous doses of  
461 BBIBP, specifically when given on days 7, 14, and 28, seems to present a limited  
462 immunological profile owing to the nature of the immune response to inactivated viruses<sup>43</sup>. In  
463 a study assessing the effectiveness of two doses of an inactivated influenza vaccine,  
464 employing a similar strategy to the development of the BBIBP vaccine, significant changes  
465 in gene expression were not observed one week after the second dose. Additionally, no  
466 considerable antibody titers were recorded, corroborating the BBIBP vaccine data<sup>44</sup>.  
467 However, in another BBIBP vaccine study, this limited immunological profile was not  
468 observed, in which a second boost induced more robust humoral and cellular immune  
469 responses detected after two weeks<sup>45</sup>. Despite the limited data regarding the efficacy of a third  
470 dose, it is evident that employing a homologous vaccination strategy with three doses of the  
471 inactivated BBIBP vaccine may offer limited immunological benefits. Nevertheless, the third  
472 dose demonstrated significant efficacy against the disease<sup>15</sup>. It is important to emphasize the  
473 need to evaluate the immune transcriptome after the first two doses in samples from infected  
474 patients who have received two or three vaccinations<sup>42</sup>. Furthermore, investigating the early

475 stages of vaccination, regardless of the number of doses administered, could provide valuable  
476 insights into identifying the genes linked to the innate immune response.

477 The Zifivax®/ZF2001 vaccine was not initially evaluated at the onset of the pandemic  
478 when the population had not yet been vaccinated. Instead, it was assessed as a booster dose in  
479 individuals who had previously received two doses of the BBIBP vaccine<sup>15</sup>. As expected, in  
480 a heterologous regimen, vaccination resulted in a distinct gene expression profile when  
481 compared to the homologous vaccine<sup>11</sup>. These findings suggest that immunological memory  
482 plays a pivotal role in the first-week post-vaccination, and antibodies generated by the  
483 inactivated vaccine recognize, opsonize, and trigger a response to the ZF2001 vaccine protein  
484 through the classical pathway of the complement system. Additionally, the original study  
485 revealed a significantly higher antibody titer than the homologous regimen, supporting the  
486 importance of heterologous vaccination<sup>15</sup>.

487 Importantly, the findings demonstrate the significant contribution of complete vaccination  
488 regimens compared to natural infection and incomplete vaccination. Considering that infected  
489 patients with incomplete vaccination were hospitalized 10-11 days after vaccination with a  
490 single dose of BNT, infection must have occurred some days before hospitalization, and we  
491 anticipated that vaccination would not have protected these patients. In the PCA, individuals  
492 with prior-vaccination overlapped between the infected cluster and the vaccination cluster C2,  
493 which encompassed homologous vaccinations for both convalescent and non-convalescent  
494 individuals, along with healthy-vaccinated individuals (**Fig. 3A**). This overlapping was  
495 notable among individuals who were infected after a complete vaccination regimen with BNT.  
496 Conversely, an incomplete vaccination regimen was associated with infection, suggesting a  
497 limited protection of vaccination administered right before infection. We found that in  
498 infected patients with no prior vaccination or with incomplete vaccination the genes related  
499 to innate immune cells and processes were highly activated and persisted for several days,  
500 especially IFN1 and IFN2, neutrophils, and APCs. Interestingly, bacterium-directed PRRs  
501 (TLR4 and NOD) were also highly expressed in these conditions, suggesting that these  
502 patients were also coinfecting by bacteria, which is a risk factor for hospitalization<sup>46</sup>.

503 To provide a model of key genes that describe infection and the different types of  
504 COVID-19 vaccines, we trained a classification random forest model with 244 genes selected  
505 from the PCA. Our model identified the 10 genes that are most important for classification,  
506 with high accuracy (91.2%) and sensitivity (ROC AUC of 99.0%), and low OOB ratio (8.6%).  
507 The genes that classified infection were associated with transcriptional regulation (GATA3,  
508 ZNF3, KMT2A, and ASXL1), antiviral response (SP100), and granzymes (GZMM); vaccine  
509 types were marked by ARPP (ITGAM, ACTG1, LGALS3) and T-cell response (STAT5B)  
510 (**Fig. 4B**).

511 In addition, we compare COVID-19 vaccines with other vaccines targeting different  
512 pathogens, as outlined in the Vax MSigDB dataset (**Fig. 5C**). This comparison is crucial for  
513 understanding how new-generation vaccines, such as mRNA-based and viral-vectored  
514 vaccines, relate to classical and consolidated vaccine technologies. Given the pivotal role of  
515 the innate immune response in the early stages of both vaccination and infection, the  
516 overlapping genes identified likely contribute to the innate immune system<sup>47</sup>. In particular,  
517 bias in FCER1G towards non-COVID-19 vaccines shows a predominance of Th2 response,  
518 presumably due to the widespread use of alum adjuvants, a known Th2 response activator that  
519 is used in the formulation of BBIBP and ZF2001<sup>48</sup>. This comparison was notable with  
520 influenza IN vaccines and LA vaccines against yellow fever and smallpox, which share  
521 common DEGs with COVID-19 vaccines in the initial weeks, especially those related to the

522 innate immune system. Additionally, LA vaccines serve as a valuable reference for a robust  
523 immune response, mimicking the wild-type virus infection. The observed overlap of LA  
524 vaccines with COVID-19 vaccination conditions adds an intriguing dimension to our findings.  
525 The diversity in the immunome in vaccines sharing the same technology may be attributed to  
526 the specific and varied nature of the adaptive immune system and other technical limitations  
527 of the MSigDB Vax dataset. It primarily relies on transcriptomic data from microarrays, which  
528 predates the widespread adoption of high-throughput RNA sequencing. In addition, this  
529 dataset lacked gene expression fold-change values, highlighting a constraint in our analysis.

530         Although this study provides valuable insights, there are notable limitations regarding  
531 the datasets and transcriptomic analyses utilized. Specifically, the use of only bulk RNA-seq  
532 data restricts our understanding of the dynamic and heterogeneous behavior of individual  
533 immune cells. Furthermore, collecting vaccination and infection samples at different time  
534 points presents a limitation in describing the chronological dynamics of the immune response.  
535 Specifically, this difference restricts the characterization of the adaptive immune response in  
536 vaccination, predominantly assessed within a one-week period. There are additional  
537 challenges in analyzing third-dose vaccinations with BNT, MO, and ChAd, which were  
538 assessed on the first-day post vaccination, primarily constraining the analysis to the innate and  
539 complement immune systems. These restrictions remain significant despite their  
540 interconnectedness with the adaptive immune responses elicited by previous doses. In  
541 addition, the analysis of BBIBP and ZF2001 vaccines is restricted by the limited time points  
542 on the days during the first week, crucial for the innate immune response, and also did not  
543 allow us to compare with the preceding doses. Moreover, the observed gene expression pattern  
544 was in agreement with the immunological finding of a study, but was contradictory to  
545 another (Aydillo et al., 2022; Ying Chen et al., 2023). Exploring how different vaccine  
546 technologies contribute to protecting infected vaccinated individuals, as observed in BNT-  
547 vaccinated individuals, would provide further insight.

548         To improve analysis and interpretation by incorporating supplementary data sources,  
549 such as antibody titers, neutralizing antibodies, T cell counts, and clinical trial data, would  
550 greatly enhance our understanding. Although sex, age, and VOCs data were present, we did  
551 not adjust the contribution of these variables to the immunological signatures described.  
552 Adopting a multidimensional approach that integrates various datasets and immunological  
553 methodologies would offer a more comprehensive understanding of the immunological  
554 landscape after vaccination.

### 555 3. Methods

#### 556 Data curation and processing

557 The selected datasets were first curated using available metadata from Gene Expression  
558 Omnibus (GEO) and supplemented with information obtained from pertinent publications  
559 (Fig. S1-3, Table 1). We included studies related to SARS-CoV-2 immunization that provided  
560 detailed and precise methodology, involved convalescent and non-convalescent patients with  
561 or without prior vaccination, and used bulk or single-cell RNA-seq PBMC-derived samples.  
562 We excluded studies that lacked methodological descriptions or references, especially  
563 concerning sample collection timing between doses, involved TCR and BCR repertoire  
564 sequencing, included patients with distinct medical conditions such as autoimmune diseases  
565 and cancer, or lacked standardized count matrices. The count matrices for each dataset were  
566 obtained from the Gene Expression Omnibus (GEO)<sup>49</sup> and their metadata from the R package  
567 GEOquery<sup>50</sup>. To standardize the gene identifiers as HGNC symbols, we used the R package  
568 biomaRT<sup>51</sup>. For reprocessing of reads in the GSE206023 study, FASTQ files were  
569 downloaded directly from GEO under the accession number GSE206023. **The details of the**  
570 **dataset and its accession numbers can be found in Supplementary Table ST1.** The  
571 average number of reads per sample was approximately 36 million after trimming, which can  
572 also be found in the supplementary material. Quality control of raw and trimmed reads was  
573 performed using FastQC v.0.11.8 (Andrews, 2010). Trimming of the adapter content and  
574 quality trimming was performed using Trimmomatic v0.36, with the following settings:  
575 LEADING 20 TRAILING 20 SLIDINGWINDOW 4:25 MINLEN 31, and the Kallisto index  
576 was built with reference transcriptome GRCh38 (Ensembl) with a k-mer length of 31 using  
577 the Kallisto v.46.0 programs, and the abundance of the transcripts was quantified using the  
578 Kallisto pseudo-alignment, which provides estimates of transcript levels<sup>17,52,53</sup>. Subsequently,  
579 we used the tximport R package to summarize count estimates at the gene level<sup>54</sup>.

#### 580 Differential gene expression analysis

581 Differential gene expression analysis was performed independently for each dataset using the  
582 R package DESeq2<sup>55</sup>. We used the Wald test with the interaction terms vaccine and time  
583 point. DEGs were filtered based on the Benjamini-Hochberg adjusted p-values ( $\text{padj} < 0.05$ ).  
584 We classified up and downregulated genes by  $\log_2$  fold change ( $-1 < \text{L2FC} < 1$ , respectively).

#### 585 Gene set enrichment analysis

586 The ontology of biological processes within the immune system ["immune system process"  
587 (GO:0002376)] was obtained from the GO.db package<sup>56</sup>. To facilitate subsequent analyses,  
588 biological processes associated with the immune system were categorized into three distinct  
589 groups: "Immune system," "Immune subsystem," and, when related to specific cells, classified  
590 under the "Immune cell" category. The VAX MSigDB database was obtained via the MSigDB  
591 portal and manually annotated with the available information on the dataset. We used only  
592 peripheral blood mononuclear cell-derived samples. The enrichment analysis of DESeq2  
593 results was conducted with ImmuneGO using the Enricher and ClusterProfiler packages for  
594 over-representation analysis (ORA) and gene set enrichment analysis (GSEA)<sup>57</sup>. Heatmaps  
595 were visualized using the ComplexHeatmap package in R and Morpheus  
596 (<https://software.broadinstitute.org/morpheus>)<sup>58,59</sup>.

## 597 **Principal component analysis and machine learning classification**

598 PCA was performed using L2FC values of immune-related DEGs, through the factoextra R  
599 package<sup>60</sup>. For cluster analysis, we used the k-nearest neighbors (KNN) algorithm. To  
600 optimize the efficiency of our random forest classification, we initially filtered genes based  
601 on their cosine squared values in the first two principal components, setting a threshold above  
602 0.5. We then constructed our random forest classifier by leveraging the tidymodels package  
603 (Kuhn & Wickam, 2020). Our dataset was partitioned into training (70%) and testing (30%)  
604 sets, with stratification for the "type" variable and upsampling to address class imbalance.  
605 Employing cross-validation, we fine-tuned the model's hyperparameters using a grid search  
606 method within the tidymodels framework. Performance evaluation metrics, including AUC,  
607 ROC, OOB, and accuracy, guided the optimization of hyperparameters, including mtry and  
608 min\_n. Finally, the optimized random forest model was trained on the entire training dataset  
609 and subsequently assessed on the testing dataset to evaluate its predictive performance.

## 610 **Data and code availability**

611 Raw and processed data, as well as codes used are available on the project Github repository  
612 ([https://github.com/wapsyed/covidvax\\_atlas](https://github.com/wapsyed/covidvax_atlas)).

## 613 **Author Contributions:**

614 WAPS, DLMF — Conceptualization and manuscript writing;

615 LV, AL, NC, EC, JSD — Manuscript contributions;

616 WAPS, DLMF, SZP — Data analysis;

617 OC, HIN, LFS, ISF, GW, RDC, NOSC, HDD, HDO, ECS, JEK – Review and editing;

618 GCM, OCM, HIN – Supervision, editing, and approval of the final version.

619 **Funding:** We thank the São Paulo Research Foundation (FAPESP grants 2019/14526-0 and  
620 2020/05146-7 to GCM; 2018/18886-9 to OCM; 2023/07806-2 to ISF; 2020/16246-2 and  
621 2023/13356-0 to DLMF; 2019/01255-9 and 2021/03684-4 to RDC) for financial support. We  
622 acknowledge the National Council for Scientific and Technological Development (CNPq)  
623 Brazil (grants: 309482/2022-4 to OCM and 102430/2022-5 to LFS).

624 **Conflicts of Interest:** The authors declare that they have no competing interests.

## 625 Tables

Vaccination								
Vaccine	Commercial name	Regimen	Timepoints (days)	Doses	Technology	Adjuvant	GSE ID	Participants
BNT162b2 (BNT)	Comirnaty	HO	0, 1, 6	3x BNT	RNA	No	GSE199750	25
		HO	0, 1, 6	2x BNT	RNA	No	GSE199750	46
		HO	0, 6	1x BNT	RNA	No	GSE199750	67
		HE	0, 1, 3, 7	1x ChAd + VV + RNA 1x BNT	No	GSE201530	16	
		HE	1	2x ChAd + VV + RNA 1x BNT	No	GSE199750	5	
		BI	10, 26, 51	2x BNT + RNA + I 1x I	No	GSE201530	13	
		BI	10, 26, 51	1x BNT (10RNA + I dpi) + 1x I	No	GSE189039	5	
		AI	10	1x BNT + RNA + I 1x I + 1x BNT	No	GSE189039	2	
		AI	0, 10, 26, 51	1x I + RNA + I + RNA + I + 1x I	No	GSE201530	1	



AZD1222 (ChAd)	Covishield, Vaxzebia	HO	0, 1, 3, 6, 7	2x ChAd	VV	No	GSE199750, 12 GSE201533
		HO	0, 3, 6	1x ChAd	VV	No	GSE199750, 53 GSE201533
		HE	0, 1, 3, 7	1x ChAd + VV + RNA 1x BNT		No	GSE201530 17
		HE	1	2x ChAd + VV + RNA 1x BNT		No	GSE199750 5
mRNA-1273 (MO)	Spikevax	HE	1	2x BNT + RNA 1x MO		No	GSE199750 10
BBIBP-CorV (BBIBP)	Covilo	HO	0, 7, 14, 28	3 (3rd dose) IN		Alum	GSE206023 6
ZF2001	Zifivax	HE	0, 7, 14, 28	1 (3rd dose) SU		Alum	GSE206023 6

626


Infection						
GSE ID	Prior infection	Prior vaccination	Timepoints (days)	Variant	Severity	Participants
GSE189039	No	Yes	0, 10, 26, 51	Beta	MI (1), S (3)	4
	No	No	0, 10, 26, 51	Beta	MO (2), S (3)	5
GSE201530	No	No	0, 1, 3, 5	Omicron	MI	1
	Yes	No	0, 1, 3, 5	Omicron	MI	6
	No	Yes	0, 1, 3, 5	Omicron	MI	38

627



628 **Table 1.** Vaccines and infection conditions selected in this study. Legend: HO: Homologous;  
629 HE: Heterologous; BI: Before infection; AI: After infection; I: Infection; RNA: mRNA; VV:  
630 Viral vector; IN: Inactivated; SU: Subunit. MI: Mild; MO: Moderate; S: Severe; A:  
631 Asymptomatic.


632 **Figures**



633

634 **Fig. 1.** Methods and description of datasets and study population. (A) We manually curated  
 635 the GEO datasets and performed differential gene expression analysis. Finally, genes from  
 636 immune system biological process (GO:) and the VAX collection from MSigDB were used  
 637 in GSEA and ORA, and individual gene expression analysis was analyzed across the studied  
 638 conditions. Created with Biorender. Number of participants (B) and samples (C) were  
 639 categorized by vaccine and infection conditions. Legend: BBIBP: BBIBP-CORV; BNT:  
 640 BNT162b2, ChAd: ChAdOx-1; MO: mRNA-1273; I: Infected; V: Vaccinated.


641



642

643 **Fig. 2.** A. Differentially expressed genes (DEGs) were categorized as up- (left panel) and  
 644 down-regulated (right panel) with the absolute and relative number of genes. The conditions  
 645 were then plotted with the total number of genes and immune genes. Labels correspond to  
 646 the total number of immune genes and the percentage over total DEGs. B. Shared DEGs between  
 647 infection and vaccination. The upper-left cluster include individuals infected for the first time,  
 648 and the bottom-right cluster comprise the first week of vaccination by RNA, VV, and SU  
 649 vaccines. C. Twenty most shared immune-related genes. Legend: BBIBP: BBIBP-CORV;  
 650 BNT: BNT162b2, ChAd: ChAdOx-1; MO: mRNA-1273; I: Infected; V: Vaccinated; IN:  
 651 Inactivated; RNA: mRNA vaccines; SU: Subunit; VV: Viral vector. B. Shared DEGs in  
 652 vaccination and infection.

Figure 3




653

654 **Fig. 3.** Principal component analysis. A. Two principal components were employed to plot all  
 655 conditions, capturing 86.2% of the total variance. K-nearest neighbors (KNN) clustering  
 656 identified three distinct clusters. Cluster 1 (C1) includes infected patients and overlaps with

657 Cluster 2 (C2). C2 is predominantly characterized by vaccination in healthy individuals,  
658 encompassing convalescent patients and non-convalescent individuals. Cluster 3 (C3)  
659 comprises the initial three days post-vaccination with mRNA vaccines and ChAd. B. The  
660 loading plot displays cos2 values for the top 20 genes in PC1 and PC2. The top 20 genes  
661 contributing to PC1 (C) and PC2 (D), along with the corresponding Log2 Fold Change  
662 (L2FC). Genes were displayed with correspondent log2-fold change ranging from -2 (blue) to  
663 2 (red). The left annotation on the heatmap depicts the contribution to different immune  
664 processes and cells, with colors corresponding to processes and cells related to the  
665 complement system (pink), the innate (greens) and adaptive immune systems (purples), and  
666 general processes and cells (leukocytes, black). Legend: BBIBP: BBIBP-CORV; BNT:  
667 BNT162b2, ChAd: ChAdOx-1; MO: mRNA-1273; I: Infected; V: Vaccinated.



Figure 4




668

669 **Fig. 4.** DEGs with  $\text{cos}2 > 0.5$  were used to train a random forest model to predict the types of  
 670 vaccines and infection, and the ten most important genes were selected (A). The final model  
 671 was selected after an iterative process of hyperparameter tuning. The best model was defined

672 with 2000 trees in the forest, where mtry was set to 6 and min\_n to 6. The most important  
673 genes were used to plot the log<sub>2</sub>-fold change (L2FC) (B). C. Gene set enrichment analysis of  
674 COVID-19 vaccines and infection. Major immunological gene sets were enriched with GSEA.  
675 Normalized enrichment scores (NES) for enriched gene sets, with circle size corresponding  
676 to  $-\log(qvalue)$ . D. Representation of upregulated (red) and downregulated (blue) genes in  
677 COVID-19 conditions associated with various immune biological processes. Visualization IN  
678 stacked hierarchical layout was generated using Cytoscape<sup>61</sup>. Node size is determined by  
679 degree centrality, and node colors are determined by type and infection status. Illustration  
680 made in **BioRender**. Legend: BBIBP: BBIBP-CORV; BNT: BNT162b2, ChAd: ChAdOx-1;  
681 MO: mRNA-1273; I: Infected; V: Vaccinated.



Figure 5



682


683 **Fig. 5.** Gene-level comparison of COVID-19 vaccines and the MSigDB Vax collection.  
 684 Overlapping immune-related (A) and other (B) genes between conditions. C. Genes with the  
 685 most sharing between COVID-19 vaccination and other vaccines. Visualization in stacked

686 hierarchical layout was generated using Cytoscape<sup>61</sup>. C. All immune-related genes shared at  
687 least once between conditions. D. Genes included in the first cluster (see complete heatmap  
688 in **Fig. S9**) were set with L2FC as 1 (upregulated) and -1 (downregulated). These genes were  
689 annotated by their corresponding contribution to subprocesses and cells among the innate,  
690 adaptive and complement immune systems (left). E. Over-representation analysis of vaccines  
691 against COVID-19 and other pathogens with immune cells and processes. Legend: BBIBP:  
692 BBIBP-CORV; BNT: BNT162b2, ChAd: ChAdOx-1; MO: mRNA-1273; I: Infected; V:  
693 Vaccinated.



694

695 Supplementary Material

696 Supplementary Figures




**All selection step 1 datasets**



698 **Fig. S1.** Data curation. Datasets were obtained from NCBI BioProject and curated. All  
 699 datasets, including the selected and non-selected, were classified by vaccine technology and  
 700 vaccination regimen, and by sample source.


701



702

703 **Fig. S2.** Description of the selected datasets. The datasets include healthy vaccinees without  
704 prior infection, infected patients without vaccination, and patients with prior full or  
705 incomplete vaccination. Sample collection timelines are shown as black lines, with red lines  
706 indicating the first sample collection during hospitalization and gray lines representing events  
707 without sample collection. Days post-infection or vaccination are depicted, with blue lines  
708 representing hospitalization periods and purple lines indicating dexamethasone treatment.







709


710 **Fig. S3.** DEGs were categorized as up- (A) and down-regulated (B) with the absolute and  
 711 relative number of genes, and grouped based on infection (red) and vaccination (blue)

712 conditions. The conditions were then plotted with the relative number of genes corresponding  
713 to their roles in essential biological processes, namely immune system, cellular processes,  
714 metabolism, and regulation of biological processes, respectively. Shapes correspond to type,  
715 colors to disease or infection, and size to total number of DEGs. I: Infection; IN: Inactivated;  
716 RNA: mRNA vaccines; SU: Subunit; VV: Viral vector.






718 **Fig. S4.** A. Shared non-immune-related DEGs between infection and vaccination. B. Twenty  
719 most shared immune-related genes. BBIBP: BBIBP-CORV; BNT: BNT162b2, ChAd:  
720 ChAdOx-1; MO: mRNA-1273; I: Infected; V: Vaccinated; IN: Inactivated; RNA: mRNA  
721 vaccines; SU: Subunit; VV: Viral vector.



722




723 **Fig. S5.** Genes related to complement system, antimicrobial response, and innate immune  
724 system processes and cells. I: Infection; IN: Inactivated; RNA: mRNA vaccines; SU: Subunit;  
725 VV: Viral vector.



726


727 **Fig. S6.** Genes related to humoral adaptive immune system, including B cell processes and  
728 immunoglobulin-mediated response. I: Infection; IN: Inactivated; RNA: mRNA vaccines;  
729 SU: Subunit; VV: Viral vector.



730

731 **Fig. S7.** Genes related to the cellular adaptive immune system, including cellular response  
 732 and T- and T helper cell processes. I: Infection; IN: Inactivated; RNA: mRNA vaccines; SU:  
 733 Subunit; VV: Viral vector.









742 **References**

- 743 1. Wang, C., Horby, P. W., Hayden, F. G. & Gao, G. F. A novel coronavirus  
744 outbreak of global health concern. *The Lancet* **395**, 470–473 (2020).
- 745 2. Chung, H. W. *et al.* Effects of government policies on the spread of COVID-19  
746 worldwide. *Sci Rep* **11**, 20495 (2021).
- 747 3. Xia, S., Wang, L., Zhu, Y., Lu, L. & Jiang, S. Origin, virological features, immune  
748 evasion and intervention of SARS-CoV-2 Omicron sublineages. *Signal*  
749 *Transduct Target Ther* **7**, 241 (2022).
- 750 4. Watson, O. J. *et al.* Global impact of the first year of COVID-19 vaccination: a  
751 mathematical modelling study. *Lancet Infect Dis* **22**, 1293–1302 (2022).
- 752 5. Li, Y. *et al.* A Comprehensive Review of the Global Efforts on COVID-19  
753 Vaccine Development. *ACS Cent Sci* **7**, 512–533 (2021).
- 754 6. World Health Organization (WHO). Status of COVID-19 Vaccines within WHO  
755 EUL/PQ evaluation process.  
756 [https://extranet.who.int/prequal/sites/default/files/document\\_files/Status\\_COVI](https://extranet.who.int/prequal/sites/default/files/document_files/Status_COVID_VAX_08August2023.pdf)  
757 [D\\_VAX\\_08August2023.pdf](https://extranet.who.int/prequal/sites/default/files/document_files/Status_COVID_VAX_08August2023.pdf) (2023).
- 758 7. Mathieu, E. *et al.* A global database of COVID-19 vaccinations. *Nat Hum Behav*  
759 **5**, 947–953 (2021).
- 760 8. Atmar, R. L. *et al.* Homologous and Heterologous Covid-19 Booster  
761 Vaccinations. *New England Journal of Medicine* **386**, 1046–1057 (2022).
- 762 9. Vasconcelos, Z. S. *et al.* Immunogenicity Characterization of COVID-19  
763 Vaccines: A Systematic Review and Meta-analysis. *Rev Soc Bras Med Trop*  
764 **56**, (2023).
- 765 10. Pollard, A. J. & Bijker, E. M. A guide to vaccinology: from basic principles to  
766 new developments. *Nat Rev Immunol* **21**, 83–100 (2021).
- 767 11. Costa Clemens, S. A. *et al.* Heterologous versus homologous COVID-19  
768 booster vaccination in previous recipients of two doses of CoronaVac COVID-

- 769 19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind,  
770 randomised study. *The Lancet* **399**, 521–529 (2022).
- 771 12. Baden, L. R. *et al.* Efficacy and Safety of the mRNA-1273 SARS-CoV-2  
772 Vaccine. *New England Journal of Medicine* **384**, 403–416 (2021).
- 773 13. Voysey, M. *et al.* Safety and efficacy of the ChAdOx1 nCoV-19 vaccine  
774 (AZD1222) against SARS-CoV-2: an interim analysis of four randomised  
775 controlled trials in Brazil, South Africa, and the UK. *The Lancet* **397**, 99–111  
776 (2021).
- 777 14. Dai, L. *et al.* Efficacy and Safety of the RBD-Dimer–Based Covid-19 Vaccine  
778 ZF2001 in Adults. *New England Journal of Medicine* **386**, 2097–2111 (2022).
- 779 15. Al Kaabi, N. *et al.* Effect of 2 Inactivated SARS-CoV-2 Vaccines on  
780 Symptomatic COVID-19 Infection in Adults. *JAMA* **326**, 35 (2021).
- 781 16. Wu, N. *et al.* Long-term effectiveness of COVID-19 vaccines against infections,  
782 hospitalisations, and mortality in adults: findings from a rapid living systematic  
783 evidence synthesis and meta-analysis up to December, 2022. *Lancet Respir*  
784 *Med* **11**, 439–452 (2023).
- 785 17. Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic  
786 RNA-seq quantification. *Nat Biotechnol* **34**, 525–527 (2016).
- 787 18. Kim, D., Paggi, J. M., Park, C., Bennett, C. & Salzberg, S. L. Graph-based  
788 genome alignment and genotyping with HISAT2 and HISAT-genotype. *Nat*  
789 *Biotechnol* **37**, 907–915 (2019).
- 790 19. Romero Starke, K. *et al.* The isolated effect of age on the risk of COVID-19  
791 severe outcomes: a systematic review with meta-analysis. *BMJ Glob Health* **6**,  
792 e006434 (2021).
- 793 20. Knabl, L. *et al.* BNT162b2 vaccination enhances interferon-JAK-STAT-  
794 regulated antiviral programs in COVID-19 patients infected with the SARS-  
795 CoV-2 Beta variant. *Communications Medicine* **2**, 17 (2022).

- 796 21. Haseeb, Pirzada, Ain & Choi. Wnt Signaling in the Regulation of Immune Cell  
797 and Cancer Therapeutics. *Cells* **8**, 1380 (2019).
- 798 22. Xiao, Y., Peperzak, V., Keller, A. M. & Borst, J. CD27 Instructs CD4+ T Cells  
799 to Provide Help for the Memory CD8+ T Cell Response after Protein  
800 Immunization. *The Journal of Immunology* **181**, 1071–1082 (2008).
- 801 23. Mohan, T., Zhu, W., Wang, Y. & Wang, B.-Z. Applications of chemokines as  
802 adjuvants for vaccine immunotherapy. *Immunobiology* **223**, 477–485 (2024).
- 803 24. Adewoye, A. B. *et al.* Human CCL3L1 copy number variation, gene expression,  
804 and the role of the CCL3L1-CCR5 axis in lung function. *Wellcome Open Res*  
805 **3**, 13 (2024).
- 806 25. Merad, M., Blish, C. A., Sallusto, F. & Iwasaki, A. The immunology and  
807 immunopathology of COVID-19. *Science (1979)* **375**, 1122–1127 (2022).
- 808 26. Afzali, B., Noris, M., Lambrecht, B. N. & Kemper, C. The state of complement  
809 in COVID-19. *Nat Rev Immunol* **22**, 77–84 (2022).
- 810 27. Almuqrin, A. *et al.* SARS-CoV-2 vaccine ChAdOx1 nCoV-19 infection of human  
811 cell lines reveals low levels of viral backbone gene transcription alongside very  
812 high levels of SARS-CoV-2 S glycoprotein gene transcription. *Genome Med*  
813 **13**, 43 (2021).
- 814 28. Liberzon, A. *et al.* Molecular signatures database (MSigDB) 3.0. *Bioinformatics*  
815 **27**, 1739–1740 (2011).
- 816 29. DiazGranados, C. A. *et al.* Efficacy of High-Dose versus Standard-Dose  
817 Influenza Vaccine in Older Adults. *New England Journal of Medicine* **371**, 635–  
818 645 (2014).
- 819 30. Piras-Douce, F. *et al.* Next generation live-attenuated yellow fever vaccine  
820 candidate: Safety and immuno-efficacy in small animal models. *Vaccine* **39**,  
821 1846–1856 (2021).
- 822 31. Behrens, R. H. & Patel, V. Avoiding shoulder injury from intramuscular  
823 vaccines. *The Lancet* **397**, 471 (2021).


- 824 32. Salgado-Albarrán, M. *et al.* Comparative transcriptome analysis reveals key  
825 epigenetic targets in SARS-CoV-2 infection. *NPJ Syst Biol Appl* **7**, 21 (2021).
- 826 33. Delorey, T. M. *et al.* COVID-19 tissue atlases reveal SARS-CoV-2 pathology  
827 and cellular targets. *Nature* **595**, 107–113 (2021).
- 828 34. Pereira, N. L. *et al.* COVID-19: Understanding Inter-Individual Variability and  
829 Implications for Precision Medicine. *Mayo Clin Proc* **96**, 446–463 (2021).
- 830 35. Liang, F. *et al.* Efficient Targeting and Activation of Antigen-Presenting Cells  
831 In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques.  
832 *Molecular Therapy* **25**, 2635–2647 (2017).
- 833 36. Karikó, K. *et al.* Incorporation of Pseudouridine Into mRNA Yields Superior  
834 Nonimmunogenic Vector With Increased Translational Capacity and Biological  
835 Stability. *Molecular Therapy* **16**, 1833–1840 (2008).
- 836 37. Xia, X. Detailed Dissection and Critical Evaluation of the Pfizer/BioNTech and  
837 Moderna mRNA Vaccines. *Vaccines (Basel)* **9**, 734 (2021).
- 838 38. Dicks, M. D. J. *et al.* A Novel Chimpanzee Adenovirus Vector with Low Human  
839 Seroprevalence: Improved Systems for Vector Derivation and Comparative  
840 Immunogenicity. *PLoS One* **7**, e40385 (2012).
- 841 39. Travieso, T., Li, J., Mahesh, S., Mello, J. D. F. R. E. & Blasi, M. The use of viral  
842 vectors in vaccine development. *NPJ Vaccines* **7**, 75 (2022).
- 843 40. Nordström, P., Ballin, M. & Nordström, A. Effectiveness of heterologous  
844 ChAdOx1 nCoV-19 and mRNA prime-boost vaccination against symptomatic  
845 Covid-19 infection in Sweden: A nationwide cohort study. *The Lancet Regional  
846 Health - Europe* **11**, 100249 (2021).
- 847 41. Wang, H. *et al.* Development of an Inactivated Vaccine Candidate, BBIBP-  
848 CorV, with Potent Protection against SARS-CoV-2. *Cell* **182**, 713-721.e9  
849 (2020).



- 850 42. Zhang, Y. *et al.* Real-world study of the effectiveness of BBIBP-CorV  
851 (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco. *BMC Public Health*  
852 **22**, 1584 (2022).
- 853 43. Sanders, B., Koldijk, M. & Schuitemaker, H. Inactivated Viral Vaccines. in  
854 *Vaccine Analysis: Strategies, Principles, and Control* 45–80 (Springer Berlin  
855 Heidelberg, 2015). doi:10.1007/978-3-662-45024-6\_2.
- 856 44. Aydililo, T. *et al.* Transcriptome signatures preceding the induction of anti-stalk  
857 antibodies elicited after universal influenza vaccination. *NPJ Vaccines* **7**, 160  
858 (2022).
- 859 45. Chen, Y. *et al.* Immunity Induced by Inactivated SARS-CoV-2 Vaccine:  
860 Breadth, Durability, Potency, and Specificity in a Healthcare Worker Cohort.  
861 *Pathogens* **12**, 1254 (2023).
- 862 46. Patton, M. J. *et al.* COVID-19 bacteremic co-infection is a major risk factor for  
863 mortality, ICU admission, and mechanical ventilation. *Crit Care* **27**, 34 (2023).
- 864 47. Sette, A. & Crotty, S. Immunological memory to <scp>SARS-CoV</scp> -2  
865 infection and <scp>COVID</scp> -19 vaccines. *Immunol Rev* **310**, 27–46  
866 (2022).
- 867 48. Pulendran, B., S. Arunachalam, P. & O’Hagan, D. T. Emerging concepts in the  
868 science of vaccine adjuvants. *Nat Rev Drug Discov* **20**, 454–475 (2024).
- 869 49. Edgar, R. Gene Expression Omnibus: NCBI gene expression and hybridization  
870 array data repository. *Nucleic Acids Res* **30**, 207–210 (2024).
- 871 50. Davis, S. & Meltzer, P. S. GEOquery: a bridge between the Gene Expression  
872 Omnibus (GEO) and BioConductor. *Bioinformatics* **23**, 1846–1847 (2007).
- 873 51. Durinck, S. *et al.* BioMart and Bioconductor: a powerful link between biological  
874 databases and microarray data analysis. *Bioinformatics* **21**, 3439–3440 (2024).
- 875 52. Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for  
876 Illumina sequence data. *Bioinformatics* **30**, 2114–2120 (2014).


- 877 53. Hunt, S. E. *et al.* Ensembl variation resources. *Database* **2018**, (2018).
- 878 54. Sonesson, C., Love, M. I. & Robinson, M. D. Differential analyses for RNA-seq:  
879 transcript-level estimates improve gene-level inferences. *F1000Res* **4**, 1521  
880 (2016).
- 881 55. Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and  
882 dispersion for RNA-seq data with DESeq2. *Genome Biol* **15**, 550 (2014).
- 883 56. Carlson, M. GO.db: A set of annotation maps describing the entire Gene  
884 Ontology. *R package version 3.8.2*.
- 885 57. Wu, T. *et al.* clusterProfiler 4.0: A universal enrichment tool for interpreting  
886 omics data. *The Innovation* **2**, 100141 (2021).
- 887 58. Gu, Z. Complex heatmap visualization. *iMeta* **1**, (2022).
- 888 59. Gu, Z., Eils, R. & Schlesner, M. Complex heatmaps reveal patterns and  
889 correlations in multidimensional genomic data. *Bioinformatics* **32**, 2847–2849  
890 (2016).
- 891 60. Lê, S., Josse, J. & Husson, F. **FactoMineR**: An R Package for Multivariate  
892 Analysis. *J Stat Softw* **25**, (2008).
- 893 61. Shannon, P. *et al.* Cytoscape: A Software Environment for Integrated Models  
894 of Biomolecular Interaction Networks. *Genome Res* **13**, 2498–2504 (2003).
- 895

A




B

Participants by vaccine




C







A






B




C












**Immune system cells and process**


- OTHER
- COMPLEMENT IMS
- INNATE IMS
- INFLAMMATION
- ANTIVIRAL AND IFN
- EOSINOPHIL
- MAST CELL
- NEUTROPHIL
- NK CELL
- ARPP
- DENDRITIC CELLS
- MACROPHAGES
- MONOCYTES
- ADAPTIVE IMS
- CELLULAR ADAPTIVE IMS
- T CELLS
- HUMORAL ADAPTIVE IMS
- IG MEDIATED RESPONSE
- B CELLS



medRxiv preprint doi: <https://doi.org/10.1101/2024.05.22.24307750>; this version posted June 8, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.



Figure 5



medRxiv preprint doi: <https://doi.org/10.1101/2024.05.22.24137755>; this version posted June 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.



Table 1

Vaccination								
Vaccine	Commercial name	Regimen	Timepoints (days)	Doses	Technology	Adjuvant	GSE ID	Participants
BNT162b2 (BNT)	Comirnaty	HO	0, 1, 6	3x BNT	RNA	No	GSE199750	25
		HO	0, 1, 6	2x BNT	RNA	No	GSE199750	46
		HO	0, 6	1x BNT	RNA	No	GSE199750	67
		HE	0, 1, 3, 7	1x ChAd + 1x BNT	VV + RNA	No	GSE201530	16
		HE	1	2x ChAd + 1x BNT	VV + RNA	No	GSE199750	5
		BI	10, 26, 51	2x BNT + 1x I	RNA + I	No	GSE201530	13
		BI	10, 26, 51	1x BNT (10 dpi) + 1x I	RNA + I	No	GSE189039	5
		AI	10	1x BNT + 1x I + 1x BNT	RNA + I	No	GSE189039	2
AZD1222 (ChAd)	Covishield, Vaxzebria	AI	0, 10, 26, 51	1x I + RNA + 1x I	I + RNA + I	No	GSE201530	1
		HO	0, 1, 3, 6, 7	2x ChAd	VV	No	GSE199750, GSE201533	12
		HO	0, 3, 6	1x ChAd	VV	No	GSE199750, GSE201533	53
		HE	0, 1, 3, 7	1x ChAd + 1x BNT	VV + RNA	No	GSE201530	17
		HE	1	2x ChAd + 1x BNT	VV + RNA	No	GSE199750	5
		HE	1	2x BNT + 1x MO	RNA	No	GSE199750	10
mRNA-1273 (MO)	Spikevax	HE	1	2x BNT + 1x MO	RNA	No	GSE199750	10
BBIBP-CorV (BBIBP)	Covilo	HO	0, 7, 14, 28	3 (3rd dose)	IN	Alum	GSE206023	6
ZF2001	Zifivax	HE	0, 7, 14, 28	1 (3rd dose)	SU	Alum	GSE206023	6

Infection						
GSE ID	Prior infection	Prior vaccination	Timepoints (days)	Variant	Severity	Participants
GSE189039	No	Yes	0, 10, 26, 51	Beta	MI (1), S (3)	4
	No	No	0, 10, 26, 51	Beta	MO (2), S (3)	5
GSE201530	No	No	0, 1, 3, 5	Omicron	MI	1
	Yes	No	0, 1, 3, 5	Omicron	MI	6
	No	Yes	0, 1, 3, 5	Omicron	MI	38

**Table 1.** Vaccines and infection conditions selected in this study. Legend: HO: Homologous; HE: Heterologous; BI: Before infection; AI: After infection; I: Infection; VV: Viral vector; IN: Inactivated; SU: Subunit. MI: Mild; MO: Moderate; S: Severe; A: Asymptomatic.